<div id="readability-page-1"><p>Zymeworks received a Buy rating and a  price target from Wells Fargo analyst Eva Fortea Verdejo today.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Fortea Verdejo covers the Healthcare sector, focusing on stocks such as Zymeworks, Merus, and Xencor. According to TipRanks, Fortea Verdejo has an average return of <span>61.2%</span> and an 89.47% success rate on recommended stocks. </p> <p>In addition to Wells Fargo, Zymeworks also received a Buy from Citi’s Yigal Nochomovitz in a report issued on December 4. However, on December 9, TR | OpenAI – 4o reiterated a Hold rating on Zymeworks (NASDAQ: ZYME).</p></div>

ZYME

<p>Wells Fargo analyst Eva Fortea Verdejo gave Zymeworks a Buy rating and set a price target, highlighting her strong track record in the healthcare sector. Citi's Yigal Nochomovitz also issued a Buy rating, while TR reiterated a Hold rating. Fortea Verdejo has a 61.2% average return and an 89.47% success rate on recommended stocks.</p>

Positive Report for Zymeworks (ZYME) from Wells Fargo